Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Receivables (2019 - 2025)

Addex Therapeutics' Change in Receivables history spans 7 years, with the latest figure at $24.0 billion for Q2 2025.

  • On a quarterly basis, Change in Receivables rose 268.43% to $24.0 billion in Q2 2025 year-over-year; TTM through Jun 2025 was -$2.8 billion, a 98.45% increase, with the full-year FY2025 number at -$5516.8, down 105.19% from a year prior.
  • Change in Receivables came in at $24.0 billion for Q2 2025, up from -$22.1 billion in the prior quarter.
  • The five-year high for Change in Receivables was $423.9 billion in Q4 2024, with the low at -$428.7 billion in Q3 2024.
  • Historically, Change in Receivables has averaged -$286.2 million across 5 years, with a median of $15006.1 in 2021.
  • Peak annual rise in Change in Receivables hit 492631036.91% in 2023, while the deepest fall reached 211928263.42% in 2023.
  • Year by year, Change in Receivables stood at $37144.2 in 2021, then tumbled by 433.12% to -$123736.4 in 2022, then tumbled by 211928263.42% to -$262.2 billion in 2023, then surged by 261.67% to $423.9 billion in 2024, then crashed by 94.34% to $24.0 billion in 2025.
  • Business Quant data shows Change in Receivables for ADXN at $24.0 billion in Q2 2025, -$22.1 billion in Q1 2025, and $423.9 billion in Q4 2024.